Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $44.00 at Scotiabank

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by equities research analysts at Scotiabank from $77.00 to $44.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank’s price target points to a potential upside of 145.67% from the company’s previous close.

A number of other analysts have also issued reports on KROS. Wedbush reaffirmed an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating and set a $102.00 price objective (up from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $85.67.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded down $0.52 during midday trading on Friday, hitting $17.91. 4,157,880 shares of the company’s stock traded hands, compared to its average volume of 452,612. The firm’s fifty day moving average price is $59.95 and its two-hundred day moving average price is $52.83. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The company has a market cap of $725.48 million, a PE ratio of -3.45 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same period last year, the firm earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. As a group, equities research analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its position in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics in the second quarter worth approximately $1,118,000. Intech Investment Management LLC bought a new position in Keros Therapeutics during the 3rd quarter valued at $603,000. Bank of New York Mellon Corp increased its position in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after purchasing an additional 18,755 shares during the period. Finally, Point72 Asset Management L.P. increased its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.